These innovative molecules represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://nicolasgkop020636.alltdesign.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-57839300